The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | Promising updates in small cell lung cancer at WCLC 2025
Kenneth O’Byrne, MD, MB, BCh, BAO, from Princess Alexandra Hospital, Brisbane, Australia, gives an overview of recent updates in small cell lung cancer (SCLC). Combining tarlatamab with atezolizumab or durvalumab in SCLC, resulted in long progression-free survivals and encouraging data that may translate to real benefits for patients in randomized controlled trials. Prof. O’Byrne additionally highlights tri-specific antibodies and the possibility of lurbinectedin in the first-line setting in limited stage SCLC. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think for me the most interesting data I’ve seen for small cell extensive stage is the combination of tarlatamab with atezolizumab and tarlatamab with durvalumab. We’ve got the two standard treatments that we use at the moment in the first line setting and that data looks very promising. You know we’re seeing very long progression-free survivals you know of magnitude we’ve never seen previously...
I think for me the most interesting data I’ve seen for small cell extensive stage is the combination of tarlatamab with atezolizumab and tarlatamab with durvalumab. We’ve got the two standard treatments that we use at the moment in the first line setting and that data looks very promising. You know we’re seeing very long progression-free survivals you know of magnitude we’ve never seen previously. Will that translate into real benefits for patients in randomized controlled trials? we don’t know because phase two type trials often select really good patients so it will translate we’ll have to wait and see but that was very very encouraging and i think also the lurbinectedin and next team data that was presented previously is a possibility and some patients are moving that into the first line setting particularly in limited stage small cell can we move tarlatamab into limited stage small cell and cancer some of the antibody drug conjugates look great and the tri-specific antibodies look great it’s all very encouraging you know that we’re going to have better effective treatments that we might lengthen people’s lives. We might cure some patients that we couldn’t cure before and limited stage disease. We might really make massive impacts.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
